Abstract
RATIONALE: An IgE-mediated allergic response requires allergen-specific B-cell differentiation into IgE-producing plasma cells. We created XmAb7195, an omalizumab (Xolair) -related anti-IgE antibody Fc engineered for high affinity to human FcγRIIb, to coengage IgE-BCR and FcγRIIb and prevent activation and terminal differentiation of IgE+ B cells. Our hypothesis is that XmAb7195 will not only sequester free IgE, but will suppress its production and reduce total IgE.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
